coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    H-blackley Harpurhey & Charlestown PCN, Manchester (LAD) · Health Inequalities Profile

    PCN U85954 · NHS Greater Manchester Integrated Care Board · 9 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    49,741

    Registered population

    61.3% aged 18–64

    12.4%

    Aged 65+

    ICB 14.9% · England 17.9%

    35.2%

    Ethnic minority (non-White)

    10.1% Asian · England 9.6%

    88.2%

    In IMD quintile 1

    ICB 40.7% · England 21.0%

    ~39,281

    Core20 residents (est.)

    Resident basis; registered basis ~44,972 · see page 3

    7,103

    Hypertension register

    +4.37% in 3 yrs · England +5.60%

    749

    SMI register

    7.9% of Manchester (LAD)'s

    1,573

    COPD register

    Reviews -2.04% in 3 yrs

    Forecast to 2030

    7,978

    Hypertension patients, 2030

    +875 on today

    77.7%

    QRISK ≥20% on statins, 2030

    +1.84pp over 3 yrs

    3.5%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    70.4%
    Pre-school booster and MMR2 uptake lag behind England.

    Age-5 4-in-1 booster coverage is 70.4% (24.6 pp below the 95.0% target) and MMR2 is 76.1%, which may reflect recall gaps (unverified locally).

    53.6%
    Non-frail diabetes HbA1c control trails national growth.

    HbA1c control (<= 58 mmol/mol) is 53.6% (1,484 of 2,767; England 57.4%), growing +0.9% over 2023 to 2025 (England +4.4%).

    73.9%
    Preventive lipid and diabetes statin prescribing exceed England.

    Lipid-lowering therapy reaches 73.9% of QRISK ≥ 20% patients (England 63.6%), alongside 81.7% primary and 89.4% secondary statin coverage in diabetes.

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Children comprise 26.3% of registered patients while ethnic minority resident share reaches 35.2%

    The PCN serves 49,741 registered patients across its practices. Children aged 0-17 represent 26.3% (13,085 patients), exceeding Manchester (LAD) (21.4%), NHS Greater Manchester ICB (21.8%) and England (19.6%). Patients aged 65+ comprise 12.4% (6,174 patients; England 17.9%). Local Census residents show a 35.2% ethnic minority share, including 18.1% Black / African / Caribbean / Black British (Manchester (LAD) 11.9%, England 4.2%), led by Church View Medical Centre (29.3%) and Fernclough Surgery (27.7%). Resident ethnicity differs from registered patient lists.

    Age profile

    0–1726.3%
    18–6461.3%
    65+12.4%

    65+: ICB 14.9%, England 17.9%

    Ethnicity

    White64.8%
    Black18.1%
    Asian10.1%
    Mixed4.4%
    Other2.6%

    Older people · falls rows are Manchester (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Manchester LA)2,3572,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)84.5%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)53.6%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Manchester LA)1,2811,0219552024/25
    Falls deaths, all ages, per 100,000 (Manchester LA)26.818.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 areas house 88.2% of registered patients, requiring dual concentration and volume targeting

    Across the PCN, 88.2% of registered patients live in Core20 areas, exceeding Manchester (LAD) (59.8%), NHS Greater Manchester ICB (40.7%) and England (21.0%), with an average IMD decile of 1.8. Church View Medical Centre, Fernclough Surgery and Willowbank Surgery each have a 100.0% Core20 share, while The Avenue Medical Centre (estimated 9,587) and Valentine Medical Centre (estimated 9,287) hold the largest Core20 volumes. Weighted practice share is 90.4%, requiring baseline reconciliation. Resources may need dual deployment between saturated full-share practices and high-volume lists.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Church View100.0% · 4,157 patients
    Fernclough100.0% · 1,937 patients
    Willowbank100.0% · 2,258 patients
    Conran97.7% · 7,318 patients
    Beacon96.6% · 4,177 patients
    Valentine89.4% · 9,287 patients
    Dam Head85.8% · 2,277 patients
    Avenue84.2% · 9,587 patients
    Charlestown Md77.3% · 3,974 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    749

    SMI register

    1.46% recorded prevalence

    463

    Learning disability register

    0.91% recorded prevalence

    19

    Care homes, 500 beds

    In the PCN catchment

    8.7%

    Provide unpaid care

    Manchester (LAD), Census 2021

    Recorded severe mental illness prevalence is 1.5% (749 patients) and learning disability prevalence is 0.9% (463 patients), both exceeding Manchester (LAD) (1.3%; 0.7%), NHS Greater Manchester ICB (1.1%; 0.6%) and England (1.0%; 0.6%). The catchment also includes 19 care homes with 500 beds. Higher recorded registers indicate substantial review cohorts, though care-home bed capacity does not establish resident patient numbers.

    Severe mental illness: physical health checks

    SMI prevalence is 1.5% (England 1.0%). Recorded blood pressure is 84.8% (England 83.4%) and BMI is 85.9% (England 82.1%). Smoking cessation offers fell 0.4 pp over 2023 to 2025 (England +0.1 pp); missing elements cannot imply completed full checks.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    7,103

    Hypertension register

    +4.37%

    Register growth, 3 yrs

    Manchester (LAD) +4.49% · England +5.60%

    +3.83pp

    BP control, under 80

    ≤140/90 · +2.42pp aged 80+

    +875

    More patients by 2030

    Forecast 7,978 (15.12%)

    Hypertension case-finding and control

    Recorded hypertension prevalence is 13.9% (7,103 patients; crude rate unadjusted for age), below England (15.2%) and NHS Greater Manchester ICB (14.4%), but above Manchester (LAD) (10.5%), with 3-year register growth of +4.4% (2023 to 2025) trailing England (+5.6%). Although recent blood pressure checks reach 91.0% (England 90.0%), treatment to target stands at 69.1%, behind England (70.3%) and the ICB (71.4%). In parallel, HbA1c control (<= 58 mmol/mol) in non-frail diabetes is 53.6% (1,484 of 2,767; England 57.4%), which could reflect titration bottlenecks (unverified locally; a medication review would test this). Treatment to target lags England despite high monitoring reach, highlighting a priority to intensify medication titration and clinical recall for uncontrolled patients.

    Lipids and statins

    Lipid-lowering therapy reaches 73.9% of patients with QRISK ≥ 20% (England 63.6%; ICB 67.0%), while statin therapy reaches 81.7% in diabetes without CVD (England 73.2%) and 89.4% with CVD (England 84.4%). Higher uptake than England demonstrates strong preventive prescribing, meaning practices should focus on sustaining long-term therapy adherence.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 2026103,348£2.00£1.94£1.86£206,696
    Cardiovascular (all), 2025143,240£2.41£3.15£3.33£345,208

    In 2026, the PCN prescribed 103,348 lipid-modifying items at £2.00 per item (£206,696 total spend), compared with £1.86 in England and £1.94 in NHS Greater Manchester ICB, spending £14,469 more than at England's unit cost. Higher unit costs than England may reflect formulary mix differences rather than inefficiency (unverified locally; a prescribing audit would test this).

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +3.07%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    −1.49%

    Asthma prevalence, PCN 3-yr % change

    Recorded COPD prevalence reached 3.1% (1,573 patients), growing +10.2% over 2023 to 2025 (England +2.6%). However, annual COPD reviews fell 2.0% over 2023 to 2025 to 77.6% (England +2.8%). Asthma prevalence is 6.6% (3,127 patients; England 6.6%), where reviews rose +3.1% over 2023 to 2025 (England +4.4%) to 67.7%, leaving an estimated scale of 1,010 unreviewed patients. Slower review growth could reflect recall capacity constraints (unverified locally; a recall audit would test this). Prescribing of asthma management items was 2,087 per 1000 aged 5-19 (England 1,488).

    Cancer register and children's immunisation

    Cancer prevalence is 2.8% (1,409 patients; England 3.8%). In childhood immunisations (Q1 2025/26), 24-month 6-in-1 coverage reached 93.0% (England 92.2%). However, 12-month 6-in-1 was 80.4% (England 91.0%), 14.6 pp below the 95.0% target. At age 5, the 4-in-1 booster reached 70.4% (England 80.9%), 24.6 pp below target. In the same age-5 cohort, MMR dose 2 (76.1%) was 11.3 pp below dose 1 (87.4%). Cohorts differ; these do not show longitudinal dropout.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months80.4%

    England 91.0%

    6-in-1 complete primary course at 24 months93.0%

    England 92.2%

    MMR dose 1 at 24 months85.3%

    England 88.3%

    MMR dose 2 at age 576.1%

    England 82.8%

    4-in-1 pre-school booster at age 570.4%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.6%

    Greater Manchester ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,270

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Greater Manchester ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%15%2,193
    Prostate61.7%53.2%14%1,788
    Breast82.5%85.4%19%1,758
    Bowel46.3%47.0%19%1,427
    Skin cancer84.5%87.8%27%580

    Across NHS Greater Manchester ICB in 2022, 55.6% of cancers with a known stage (6,491 of 11,679) were diagnosed at stage 1 or 2 (England 55.3%), 19.4 percentage points below the 75.0% national ambition by 2028. Known-stage coverage was 70.8% (11,679 of 16,492; England 67.0%), leaving 2,268.2 extra cases needed to reach 75.0%. Staging data was not captured at PCN level. PCN breast screening coverage is 50.8% (England 69.9%, Manchester (LAD) 59.3%), despite a +31.5% three-year rise (2023 to 2024; England +8.4%), with Charlestown Md at 37.7%, Fernclough Surgery at 41.7%, and Beacon Medical Centre at 48.7%.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    At Manchester University NHS Foundation Trust, the 62-day referral to treatment standard stood 12.2 percentage points below the 85.0% standard. The 28-day faster diagnosis standard was 5.1 percentage points above the 75.0% standard, and the 31-day standard was 3.5 percentage points below the 96.0% standard. For NHS Greater Manchester Integrated Care Board, the 62-day standard was 9.3 percentage points below the 85.0% standard, the 28-day standard was 4.5 percentage points above 75.0%, and the 31-day standard was 0.5 percentage points above 96.0%. These trust and ICB figures describe the wider system; PCN waiting times were not captured.

    Pathways within standard (%)ManchesterNorthern Care AllianceTameside and Glossop Integrated CareGreater Manchester ICBEngland
    28-day faster diagnosis (75%)80.0675.2082.4879.5379.32
    31-day treatment (96%)92.5494.5496.2596.4992.50
    62-day referral to treatment (85%)72.8578.6576.7775.7371.16
    Diagnostic waits over 6 weeks (%)ManchesterNorthern Care AllianceTameside and Glossop Integrated CareEngland
    MRI11.685.090.0021.40
    CT14.664.100.189.92
    Echocardiography4.9131.480.0028.48
    Colonoscopy4.5140.041.5130.83
    Gastroscopy29.3536.485.4529.02
    All 15 DM01 tests8.9815.710.8023.14
    Community services activityManchester residentsGreater Manchester ICB
    Care contacts96,995573,310
    Referrals20,27094,470
    Patients with a contact31,040183,535

    Community services (residents of Manchester), Jun 2026 (provisional). In the Community Services Dataset for June 2026 (provisional), adults aged 65 and over accounted for 43.3% of community contacts among Manchester local authority residents (42,015 of 96,995 contacts). Provider-specific and PCN-level community activity data were not captured; this describes borough-level activity rather than PCN performance.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Personalised care adjustment rates range from 5.8% to 13.7% across practices in 2025/26

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Beacon10596.676.8%71.2%87.4%
    Church View114100.069.0%82.7%87.3%
    Fernclough Surgery100100.083.7%72.9%84.5%
    Valentine9889.457.6%78.1%84.3%
    Willowbank Surgery85100.076.4%86.3%76.4%
    Dam Head11585.865.2%73.5%75.9%
    Conran8497.781.1%83.5%75.1%
    Avenue9384.247.6%77.7%71.9%
    Charlestown Md9277.347.1%80.2%70.9%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNManchester (LAD)AssetPCNManchester (LAD)
    Care homes (catchment)19 (500 beds)n/aSchools (catchment)62n/a
    Children's centres534Places of worship40289
    Libraries316Homelessness support (VCS)n/a1
    Primary schools (LA maintained)1568Primary academies850
    Special schools13

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma review and recall

    Asthma review coverage is 67.7% (England 65.7%), but 3-year growth (+3.1%, 2023 to 2025) lagged England (+4.4%), leaving an estimated 1,010 of 3,127 patients unreviewed. For discussion, the PCN could run single-template asthma recall and after-school review slots alongside inhaler prescribing checks. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    Diabetes and hypertension titration recall

    Non-frail diabetes HbA1c <= 58 mmol/mol is 53.6% (1,484 of 2,767 in 2024/25; England 57.4%) and hypertension treatment to target is 69.1% (England 70.3%). For discussion, the PCN could establish pharmacist-led recall and titration clinics for uncontrolled non-frail diabetes and hypertension patients. Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 3

    Pre-school booster and MMR2 recall

    In Q1 2025/26 (cohort 160), age-5 4-in-1 coverage is 70.4% (England 80.9%; ICB 80.5%) and MMR2 is 76.1% (England 82.8%), 11.3 pp below MMR1 (87.4%). For discussion, practices could run targeted age-5 recall with flexible clinic times and adapted invitations for overdue boosters. Moderate effort to run.

    Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.

    Policy anchor: 10 Year Health Plan, shift from sickness to prevention.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Culturally tailored health outreach (p2)Black / African / Caribbean / Black BritishNeighbourhood health framework · Core20PLUS5 approachPCN
    Differentiated Core20 outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    Smoking cessation support review (p4)Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs)MHIS · From Harm to HopePCN
    Hypertension review and titration clinics (p5)Hypertension: QOF prevalenceCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Preschool booster recall outreach (p6)4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% targetPCN
    Targeted breast screening recall outreach (p7)Breast screening coverage: aged 53 to 70 years old—PCN
    Option 1 · Structured asthma review and recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 2 · Diabetes and hypertension titration recall (p12)Hypertension register · Hypertension: QOF prevalence · Hypertension patients treated to targetCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Option 3 · Pre-school booster and MMR2 recall (p12)4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · MMR dose 2 coverage at age 5 · MMR dose 1 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15